Effects of sulfasalazine in axial spondyloarthritis on COVID-19 outcomes: real-life data from a single center.
Armagan BerkanEbru AtalarSerdar Can GüvenBahar ÖzdemirHatice Ecem KonakPınar Akyüz DağlıAbdulsamet ErdenKevser GökYüksel Maraşİsmail DoğanOrhan KücüksahinŞükran ErtenAhmet OmmaPublished in: Immunopharmacology and immunotoxicology (2022)
Our results imply sulfasalazine may be related to more severe COVID-19 in AxSpA patients. These patients should be followed more carefully in the presence of COVID-19, regardless of reasons such as age, comorbidity, and extra-axial disease, and consideration of discontinuing sulfasalazine maybe even thought.
Keyphrases
- coronavirus disease
- end stage renal disease
- sars cov
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- patient reported outcomes
- adipose tissue
- machine learning
- systemic lupus erythematosus
- respiratory syndrome coronavirus
- electronic health record
- weight loss
- disease activity
- drug induced